Related Experiment Videos
[Rickets prophylaxis by daily administration of vitamin D tablets (author's transl)]
Insights
Daily vitamin D3 microtablets effectively prevent deficiency in newborns, including premature infants. This study found no significant difference in efficacy compared to liquid vitamin D preparations.
Area of Science:
- Pediatrics
- Nutritional Science
- Endocrinology
Context:
- Neonatal vitamin D deficiency is a significant concern, particularly in premature infants who have higher nutritional demands.
- Ensuring adequate vitamin D levels is crucial for bone health and overall development in newborns.
- Existing vitamin D prophylaxis often involves liquid formulations, which may present challenges in administration and dosing accuracy.
Purpose:
- To evaluate the efficacy of a daily oral vitamin D3 microtablet formulation (Laevovit D3, 1000 IU) for prophylaxis in newborn infants.
- To assess the serum levels of 25-hydroxycholecalciferol as a biomarker of vitamin D status at one and five weeks post-initiation.
- To compare the effectiveness of vitamin D3 microtablets against traditional liquid vitamin D preparations.
Summary:
- A 5-week study assessed daily 1000 IU vitamin D3 microtablets in newborns, primarily premature infants.
- Serum 25-hydroxycholecalciferol levels were measured, indicating protective ranges against deficiency in most infants.
- No significant difference in efficacy was observed between the microtablet and liquid vitamin D formulations.
Impact:
- Provides evidence supporting the use of vitamin D3 microtablets as a viable and effective alternative for neonatal prophylaxis.
- May improve adherence and ease of administration for vitamin D supplementation in infants.
- Contributes to the understanding of optimal vitamin D supplementation strategies for vulnerable neonatal populations.
Abstract:
The efficiency of a daily vitamin D prophylaxis with tablets ("Laevovit D3"), containing 1000 I.U. cholecalciferol was studied in newborn babies (most of them "prematures") over a period of about 5 weeks. The blood-values of 25-hydroxycholecalciferol were taken as parameter and determined 1 week and 5 weeks after the start of vitamin D prophylaxis. The data obtained were--with very few exceptions-- in a range considered to be protective against development of vitamin D deficiency. No significant difference could be found comparing vitamin D prophylaxis with these "microtablets" vs. liquid vitamin D preparations.